ATE333464T1 - Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika - Google Patents

Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika

Info

Publication number
ATE333464T1
ATE333464T1 AT98907779T AT98907779T ATE333464T1 AT E333464 T1 ATE333464 T1 AT E333464T1 AT 98907779 T AT98907779 T AT 98907779T AT 98907779 T AT98907779 T AT 98907779T AT E333464 T1 ATE333464 T1 AT E333464T1
Authority
AT
Austria
Prior art keywords
compositions
methods
antibiotics
combination
treating infections
Prior art date
Application number
AT98907779T
Other languages
English (en)
Inventor
Janet R Fraser
Michael H P West
Patricia J Mcnicol
Original Assignee
Migenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/915,314 external-priority patent/US6180604B1/en
Application filed by Migenix Inc filed Critical Migenix Inc
Application granted granted Critical
Publication of ATE333464T1 publication Critical patent/ATE333464T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT98907779T 1997-03-10 1998-03-10 Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika ATE333464T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4064997P 1997-03-10 1997-03-10
US08/915,314 US6180604B1 (en) 1996-08-21 1997-08-20 Compositions and methods for treating infections using analogues of indolicidin
US6009997P 1997-09-26 1997-09-26
US09/030,619 US6503881B2 (en) 1996-08-21 1998-02-25 Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics

Publications (1)

Publication Number Publication Date
ATE333464T1 true ATE333464T1 (de) 2006-08-15

Family

ID=27487830

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98907779T ATE333464T1 (de) 1997-03-10 1998-03-10 Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika

Country Status (9)

Country Link
US (3) US6503881B2 (de)
EP (1) EP0966481B1 (de)
JP (1) JP2002544759A (de)
AT (1) ATE333464T1 (de)
AU (1) AU6604798A (de)
CA (1) CA2282807A1 (de)
DE (1) DE69835279T2 (de)
ES (1) ES2264198T3 (de)
WO (1) WO1998040401A2 (de)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6172185B1 (en) * 1998-05-20 2001-01-09 University Of British Columbia Antimicrobial cationic peptide derivatives of bactenecin
GB9818938D0 (en) 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
WO2000026344A1 (en) * 1998-10-30 2000-05-11 Interlink Biotechnologies Llc Peptides with enhanced stability to protease degradation
US6946261B1 (en) 1998-11-20 2005-09-20 Migenix Inc. Efficient methods for producing anti-microbial cationic peptides in host cells
MXPA01007806A (es) * 1999-02-03 2003-06-04 Biogal Gyogyszergyar Proceso para la preparacion del antibiotico acido pseudomonico a mediante un metodo microbiologico.
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US20030008369A1 (en) * 1999-03-03 2003-01-09 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of ABC transporters and ecto-phosphatases
WO2000055337A1 (en) * 1999-03-17 2000-09-21 University Of Victoria Innovation And Development Corporation Transgenic plants that are resistant to a broad spectrum of pathogens
US6835868B1 (en) 1999-03-17 2004-12-28 University Of Victoria Innovation And Development Corporation Transgenic plants expressing dermaseptin peptides providing broad spectrum resistance to pathogens
WO2001001957A1 (en) * 1999-05-27 2001-01-11 Biocompatibles Limited Local drug delivery
US7015309B1 (en) 1999-06-23 2006-03-21 The Wistar Institute Of Anatomy And Biology Pyrrhocoricin-derived peptides, and methods of use thereof
ECSP003699A (es) * 1999-10-08 2002-04-23 Smithkline Beecham Corp Inhibidores de fab i
US20030134779A1 (en) * 1999-12-20 2003-07-17 Diarra Moussa S. Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections
AU2795801A (en) * 2000-01-21 2001-07-31 Creighton University Biocidal molecules, macromolecular targets and methods of production and use
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US6632616B2 (en) * 2000-03-16 2003-10-14 Duke University Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
US6777592B2 (en) * 2000-04-14 2004-08-17 E.I. Du Pont Denemours And Company Arthropod defensins of Scolopendra canidens, Vaejovis carolinianus, and Argiope spp.
DE10030781A1 (de) * 2000-06-29 2002-01-17 Hassan Jomaa Kombinationspräparate von 3-N-Formylhydroxylaminopropylphosphonsäurederivaten oder 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten mit spezielen pharmazeutischen Wirkstoffen
DE10042853A1 (de) * 2000-08-30 2002-04-25 Florian Lang Nachweis und Beeinflußung der Expression oder Funktion von CD95/CD95L bei Infektionen
CA2433910A1 (en) * 2001-01-05 2002-10-10 Richard M. Austin, Jr. Antibiotics from bacteria isolated from amphibian skin
WO2002064183A1 (en) * 2001-02-09 2002-08-22 Johnson & Johnson Vision Care, Inc. Biomedical devices with antimicrobial cationic peptide and protein coatings
DE60230934D1 (de) * 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
CZ200467A3 (cs) * 2001-06-21 2004-10-13 Biogalágyogyszergyarárt Metabolicky řízený způsob fermentace pro výrobu pseudomonové kyseliny
JP2004534084A (ja) * 2001-06-22 2004-11-11 ザ ホスピタル フォー シック チルドレン 抗菌ペプチド
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
WO2003018619A2 (en) * 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
KR100438416B1 (ko) * 2001-09-19 2004-07-02 학교법인조선대학교 Ｃａ－ｍａ 펩타이드의 아미노산 중 하나 또는 그 이상을치환하여 ＋ 전극과 소수성 영역이 증가된 신규한펩타이드 및 그를 포함하는 약학적 조성물
CA2462871C (en) * 2001-10-05 2013-07-02 Steris Inc. In vitro model for priocidal activity
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
CN1625394A (zh) 2001-12-28 2005-06-08 拜奥盖尔药厂有限公司 结晶和无定形莫匹罗星钙的制备方法
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20030219854A1 (en) * 2002-03-21 2003-11-27 Micrologix Biotech Inc. Methods for producing modified anti-infective peptides
KR20040094855A (ko) * 2002-03-26 2004-11-10 이스턴 버지니아 메디컬 스쿨 국소용 살균제 및 피임제로서의 수라민 또는 그 유도체
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
FR2839311A1 (fr) * 2002-05-06 2003-11-07 Entomed Peptides antibacteriens, genes codant les peptides, vecteurs, organismes transformes, leurs preparations et les compositions les contenant
EP1360961A1 (de) * 2002-05-07 2003-11-12 AM-Pharma B.V. Verwendung von antimikrobiell wirkenden Peptiden zur Aktivitätssteigerung von antimikrobiellen Wirkstoffen
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
EP3427742B1 (de) * 2002-10-29 2020-08-12 Insmed Incorporated Aminoglycosid enthaltende liposome zur behandlung von pulmonaren infektionen
EP1575951B1 (de) 2002-12-06 2014-06-25 Debiopharm International SA Heterozyclische verbindungen, verfahren zu deren herstellung und ihre verwendung als heilmittel
AP2005003346A0 (en) * 2002-12-10 2005-06-30 Biosynexus Inc Topical anti-infective formulations
DE10260537A1 (de) * 2002-12-21 2004-07-15 Kerek, Franz, Dr. Peptide mit hohem Cysteingehalt
WO2004082586A2 (en) * 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
WO2004098643A1 (en) * 2003-04-14 2004-11-18 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
PT1468697E (pt) * 2003-04-14 2008-03-05 Wyeth Corp Composições contendo piperacilina e tazobactam úteis para injecção
US6989370B2 (en) * 2003-05-01 2006-01-24 The United States Of America As Represented By The Secretary Of Agriculture Bacteriocins and novel bacterial strains
SE0301431D0 (sv) 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
CA2530927A1 (en) 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US20060121083A1 (en) * 2003-07-18 2006-06-08 Technion Research & Development Foundation Ltd. Anti-microbial medical implants and uses thereof
AU2003904225A0 (en) * 2003-08-08 2003-08-21 Ripetech Pty Limited Method for reducing precure during the curing of thermosetting resins
BRPI0413521A (pt) 2003-08-14 2006-10-10 Diatos seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares
FR2858772A1 (fr) * 2003-08-14 2005-02-18 Diatos Composition anti bacterienne, plus particulierement contre les bacteries gram negatif, comprenant un peptide et un agent anti-bacterien avantageusement hydrophobe
US7455840B2 (en) * 2003-11-19 2008-11-25 The Scripps Research Institute Compositions and methods to reduce mutagenesis
US20050108047A1 (en) * 2003-11-19 2005-05-19 Vvii Newco 2003, Inc. Business methods for commercializing antibiotics
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
WO2005089738A2 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
WO2005090385A2 (en) * 2004-03-18 2005-09-29 Ansata Therapeutics, Inc. Compositions having antimicrobial activity and uses thereof
ES2339682T3 (es) * 2004-06-01 2010-05-24 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Procedimiento para la preparacion de la forma amorfa de un farmaco.
US8450307B2 (en) 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1778720B1 (de) * 2004-08-18 2010-09-01 Novabiotics Limited Antimikrobielle peptide mit einem arginin- und /oder lysin-haltigen motiv
US7700308B2 (en) * 2004-09-16 2010-04-20 University Of Washington Methods for determining susceptibility to dental caries
WO2006049580A1 (en) * 2004-11-04 2006-05-11 National University Of Singapore Anticoagulant peptides
EP1657249A1 (de) * 2004-11-10 2006-05-17 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Antibiotisch wirksame Drosocinderivate
SE0402807D0 (sv) * 2004-11-17 2004-11-17 Dermagen Ab Novel antimicrobial peptides
WO2006065977A2 (en) 2004-12-15 2006-06-22 The Regents Of The University Of Colorado Antimicrobial peptides and methods of use
CN102512429A (zh) * 2005-03-14 2012-06-27 惠氏公司 替加环素组合物及制备方法
US20060286574A1 (en) * 2005-04-05 2006-12-21 The Scripps Research Institute & Achaogen, Inc. Compositions and methods for enhancing drug sensitivity and treating drug resistant infections and diseases
CA2617133C (en) * 2005-07-28 2014-09-30 Biosynexus Incorporated Compositions and methods for treating bacteria
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
EP1987056B1 (de) * 2006-02-10 2012-07-25 Dermagen AB Neue antimikrobielle peptide und deren anwendung
US20090312265A1 (en) * 2006-02-10 2009-12-17 Dermagen Ab Novel antimicrobial peptides and use thereof
JP5600432B2 (ja) * 2006-04-06 2014-10-01 インスメッド， インコーポレイテッド コアセルベート化誘導リポソーム被包法及びその調合物
KR101487719B1 (ko) * 2006-05-16 2015-01-29 페르가뭄 아베 개선된 항미생물성 펩타이드
IL176303A0 (en) * 2006-06-14 2006-10-05 Shmuel Shraga Pharmaceutical composition for the treatment of otomycosis
EP2687533B1 (de) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamidderivate als FAB-I-Hemmer
WO2008033119A1 (en) * 2006-09-12 2008-03-20 Chaperone Technologies, Inc. Novel combinations of dnak inhibitors with known antibacterial agents
US20080139518A1 (en) * 2006-12-04 2008-06-12 Concert, Llc Topical compositions for treatment of skin conditions
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US20100196455A1 (en) * 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
WO2009009156A2 (en) * 2007-07-06 2009-01-15 Laclede, Inc. Use of hydrolytic and oxidative enzymes to dissolve biofilm in airway passages
DE102007036128A1 (de) * 2007-07-23 2009-02-12 Universität Leipzig Antibiotische Peptide
EP2197463A2 (de) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Verwendung von rgdspasskp und optional angiotensin-ii als therapeutische mittel zur behandlung von z.b. infektionen mit s. pneumoniae
AU2008297893A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a deslorelin and mastoparan as a therapeutic agent
DE102008031284A1 (de) * 2008-07-02 2010-01-07 Bayer Schering Pharma Aktiengesellschaft Neue Bekämpfungsmöglichkeit der Giardiose
DE102008031283A1 (de) * 2008-07-02 2010-01-07 Bayer Schering Pharma Aktiengesellschaft Neue Bekämpfungsmöglichkeit von durch Trichomonadida hervorgerufenen Krankheiten
US20100008897A1 (en) * 2008-07-09 2010-01-14 Susan Daly Composition for providing a benefit to a keratin-containing substrate
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
EP2346521A4 (de) * 2008-10-06 2012-06-20 Univ Colorado Regents Peptide und verwendungsverfahren dafür
WO2010141760A2 (en) * 2009-06-05 2010-12-09 The Regents Of The University Of Colorado, A Body Corporate Antimicrobial peptides
EP2446028B1 (de) * 2009-06-26 2018-04-04 Lysando Aktiengesellschaft Antimikrobielle wirkstoffe
PL2445515T3 (pl) 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
TW201125577A (en) * 2009-12-02 2011-08-01 Novozymes As Use of defensins for treatment of infective endocarditis
AU2011330768A1 (en) 2010-11-15 2013-05-30 Merz Pharma Gmbh & Co. Kgaa Dipeptide analogs for treating conditions associated with amyloid fibril formation
US20130345249A1 (en) * 2011-01-15 2013-12-26 The Regents Of The University Of California Formulations for the prevention and treatment of Wolbachia-related disease
ES2905368T3 (es) 2012-05-21 2022-04-08 Insmed Inc Sistemas para el tratamiento de infecciones pulmonares
KR101720885B1 (ko) 2012-06-19 2017-03-28 데비오팜 인터네셔날 에스 에이 (e)-n-메틸-n-((3-메틸벤조푸란-2-일)메틸)-3-(7-옥소-5,6,7,8-테트라히드로-1,8-나프티리딘-3-일)아크릴아미드의전구약물 유도체
WO2014085526A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US9096679B2 (en) 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
JP6377070B2 (ja) 2012-12-03 2018-08-22 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ ペプチド化合物及びその製造方法及びその使用
US20200157159A1 (en) 2013-04-16 2020-05-21 The Board Of Regents Of The University Of Oklahoma Peptide compounds and compositions thereof
DK2986309T3 (en) 2013-04-16 2018-05-07 Univ Oklahoma PEPTIME RELATIONS AND PROCEDURES FOR PREPARING AND USING THEREOF
HRP20200599T1 (hr) 2013-05-10 2020-08-07 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Antimikrobijalni peptid
KR101550965B1 (ko) * 2013-07-31 2015-09-07 씨제이제일제당 (주) 초고압을 이용한 야채류 식품의 제조방법
US10059752B2 (en) * 2013-10-14 2018-08-28 University Of Houston System Esculentin 1a derivatives and uses thereof
US10751440B2 (en) * 2013-10-14 2020-08-25 University Of Houston System Esculentin 1a derivatives and uses thereof
JP6494616B2 (ja) * 2013-10-31 2019-04-03 ハチソン バイオフィルム メディカル ソリューションズ リミテッド バイオフィルムの予防及び分散
CN105813695A (zh) 2013-11-01 2016-07-27 斯弗尤姆生物制药有限公司 用于透皮递送治疗剂和美容剂的包含体
PL3142643T3 (pl) 2014-05-15 2019-12-31 Insmed Incorporated Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
US10791740B2 (en) 2014-06-06 2020-10-06 The Curators Of The University Of Missouri Enhancement of antibiotic efficacy
EP4134076A1 (de) * 2014-10-24 2023-02-15 Redhill Biopharma Ltd. Therapie zur hemmung der replikation eines einzelsträngigen rna-virus
EP3197479B1 (de) * 2015-02-22 2019-06-26 Omnix Medical Ltd. Antimikrobielle peptide
KR101773390B1 (ko) * 2015-05-08 2017-08-31 동아인코팜 주식회사 여드름 개선용 화장료 조성물
CN109562137A (zh) 2015-09-01 2019-04-02 第波生物公司 用于治疗与异常炎性反应有关的病况的方法和组合物
AU2017224113B2 (en) 2016-02-25 2022-04-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
RS61312B1 (sr) 2016-02-26 2021-02-26 Debiopharm Int Sa Lek za lečenje infekcija dijabetskog stopala
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
ITUA20163612A1 (it) 2016-05-19 2017-11-19 Icf Srl Nuovi composti attivi contro microorganismi patogeni
US11213512B2 (en) 2016-06-21 2022-01-04 The Curators Of The University Of Missouri Bis-amino acid based compound and use thereof
CN106589135B (zh) * 2016-11-25 2018-08-28 东北农业大学 一种靶向抗菌肽及其制备方法和应用
AU2018213284B2 (en) 2017-01-24 2024-03-28 Flagship Pioneering Innovations V, Inc. Compositions and related methods for agriculture
CN111148523A (zh) 2017-01-24 2020-05-12 旗舰创业创新五公司 用于控制媒介传播的疾病的组合物和相关方法
SG11201905788VA (en) 2017-01-24 2019-08-27 Flagship Pioneering Innovations V Inc Methods and related compositions for manufacturing food and feed
CN110869038A (zh) 2017-01-24 2020-03-06 旗舰创业创新五公司 用于控制媒介传播的疾病的组合物和相关方法
WO2018140519A1 (en) * 2017-01-24 2018-08-02 Flagship Pioneering, Inc. Compositions and related methods for agriculture
JP7231551B2 (ja) 2017-02-24 2023-03-01 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 内部共生体を調節するための組成物及び関連方法
EP3773505A4 (de) 2018-03-30 2021-12-22 Insmed Incorporated Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
AU2019262117C1 (en) 2018-05-02 2024-12-05 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
CN108434438B (zh) * 2018-06-22 2020-08-25 安徽科技学院 抗菌肽在制备治疗幽门螺杆菌病的药物中的用途以及药物组合物
MY203711A (en) 2019-02-14 2024-07-15 Debiopharm Int Sa Afabicin formulation, method for making the same and uses thereof
JP7418475B2 (ja) 2019-06-14 2024-01-19 デバイオファーム インターナショナル エス．エー． バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用
US11471433B1 (en) 2019-08-01 2022-10-18 Flagship Pioneering Innovations V, Inc. Postbiotic compositions and related methods for agriculture
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
EP4208157A1 (de) 2020-09-04 2023-07-12 Elanco Us Inc. Wohlschmeckende formulierungen
WO2022061096A1 (en) * 2020-09-17 2022-03-24 Board Of Regents, The University Of Texas System Pharmaceutical compositions of niclosamide and a protein
WO2026041926A1 (en) 2024-08-22 2026-02-26 Itc Limited A synergistic combination of an antimicrobial peptide and actives for hygiene applications
WO2026042045A1 (en) 2024-08-22 2026-02-26 Itc Limited Indolicidine-containing compositions for personal care/hygiene applications
WO2026041925A1 (en) 2024-08-22 2026-02-26 Itc Limited A synergistic composition of an antimicrobial peptide (amp) and natural active
CN119350439B (zh) * 2024-08-26 2025-12-30 海南大学 一种具有抗白色念珠菌活性的短链抗菌肽及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
US5324716A (en) 1991-06-14 1994-06-28 Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5547939A (en) 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
DE69430823T2 (de) 1993-09-22 2003-02-20 Xoma Technology Ltd., Berkeley Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
PT754050E (pt) 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US5877274A (en) * 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
DE69637731D1 (de) * 1995-08-23 2008-12-11 Univ British Columbia Antimikrobielle kationische peptide und methoden zu ihrer identifizierung
US5994308A (en) 1996-02-28 1999-11-30 Board Of Trustees Of Southern Illinois University Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
AU2605099A (en) 1998-02-25 1999-09-15 Micrologix Biotech, Inc. Indolicidin and cationic peptides conjugated with polymers

Also Published As

Publication number Publication date
AU6604798A (en) 1998-09-29
US20110150780A1 (en) 2011-06-23
EP0966481A2 (de) 1999-12-29
WO1998040401A2 (en) 1998-09-17
DE69835279D1 (de) 2006-08-31
CA2282807A1 (en) 1998-09-17
US7309759B2 (en) 2007-12-18
WO1998040401A3 (en) 1998-12-17
JP2002544759A (ja) 2002-12-24
EP0966481B1 (de) 2006-07-19
US20020035061A1 (en) 2002-03-21
ES2264198T3 (es) 2006-12-16
HK1025103A1 (en) 2000-11-03
US6503881B2 (en) 2003-01-07
DE69835279T2 (de) 2007-07-12
US20030232750A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
ATE410441T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
ATE393831T1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
DE69732871D1 (de) Basisches Protein Zusammensetzung, basisches Peptid Zusammensetzung und deren Verwendung
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
TW224055B (de)
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
WO1993023434A3 (en) Bpi-immunoglobulin fusion proteins
GR3019901T3 (en) Osteoinductive pharmaceutical formulations
ATE338771T1 (de) Antagonisten des intestinotrophen glp-2 peptides
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
GR3024379T3 (en) Peptides with organo-protective activity, the process for preparing them and their use in therapy
CA2131565A1 (en) Organopolysiloxanes Containing Hydrophilic Groups
EP1401467A4 (de) Alpha-fetoprotein-peptide und ihre verwendung
ATE408685T1 (de) Antimikrobielle peptide, abstammend von ubiquicidin
LV11816A (lv) Implantejama zalu forma
WO2003063775A3 (en) Methods and compositions for the promotion of hair growth utilizing actin binding peptides
EP1174439A3 (de) Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
PT938329E (pt) Composicao de tlp imunogenica
PL351376A1 (en) Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines
DE60234843D1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
DE69534738D1 (de) Leukocyten-aktivierender Faktor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties